Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients

Breast Cancer Research and Treatment

Volumn 152, Issue 1, 2015, Pages 119-128

  Binkhorst, Lisette ^a,b   Kloth, Jacqueline S L ^a   de Wit, Annelieke S ^b   de Bruijn, Peter ^a   Lam, Mei H ^a   Chaves, Ines ^b   Burger, Herman ^a   van Alphen, Robbert J ^c   Hamberg, Paul ^d   van Schaik, Ron H N ^b   Jager, Agnes ^a   Koch, Birgit C P ^b   Wiemer, Erik A C ^a   van Gelder, Teun ^b   van der Horst, Gijsbertus T J ^b   Mathijssen, Ron H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Breast cancer; Circadian variation; Endocrine therapy; Pharmacokinetics; Tamoxifen

Indexed keywords

CYP2D10 PROTEIN; CYP2D22 PROTEIN; MESSENGER RNA; OXIDOREDUCTASE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GENE EXPRESSION; HOT FLUSH; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOOD DISORDER; MORNING DOSAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; ANIMAL; BREAST NEOPLASMS; CROSSOVER PROCEDURE; DISEASE MODEL; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETICS;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MIDDLE AGED; PHARMACOGENETICS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84931011765     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3452-x     Document Type: Article

References (29)

1. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
2. Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576–586. doi:10.1038/nrc2683
3. Schiavon G, Smith IE (2013) Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin N Am 27:715–736, viii. doi:10.1016/j.hoc.2013.05.004
4. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, German T, Group AIC, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717. doi:10.1038/clpt.2011.27
5. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764
6. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175–2183
7. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725. doi:10.1038/clpt.2011.32
8. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74. doi:10.1016/j.clpt.2006.03.013
9. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436. doi:10.1001/jama.2009.1420
10. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sorensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S (2011) CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 103:489–500. doi:10.1093/jnci/djr010
11. Aubert RE, Yao J, Teagarden JR, Subar M, Epstein RS, Skaar TC, Desta Z, Flockhart DA (2009) Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27(suppl):18 s (abstr CRA508)
12. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, Trialists A (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452–460. doi:10.1093/jnci/djs126
13. Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB (2013) CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 139:95–105. doi:10.1007/s10549-013-2511-4
14. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH (2012) Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther 92:62–67. doi:10.1038/clpt.2011.372
15. Baraldo M (2008) The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 4:175–192. doi:10.1517/17425255.4.2.175
16. Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA (2010) The role of clock genes in pharmacology. Annu Rev Pharmacol Toxicol 50:187–214. doi:10.1146/010909.105621
17. Ohdo S, Koyanagi S, Matsunaga N, Hamdan A (2011) Molecular basis of chronopharmaceutics. J Pharm Sci 100:3560–3576. doi:10.1002/jps.22656
18. Binkhorst L, Mathijssen RH, Ghobadi Moghaddam-Helmantel IM, de Bruijn P, van Gelder T, Wiemer EA, Loos WJ (2011) Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J Pharm Biomed Anal 56:1016–1023. doi:10.1016/j.jpba.2011.08.002
19. Zhang YK, Yeager RL, Klaassen CD (2009) Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos 37:106–115. doi:10.1124/dmd.108.024174
20. Goo RH, Moore JG, Greenberg E, Alazraki NP (1987) Circadian variation in gastric emptying of meals in humans. Gastroenterology 93(3):515–518
21. Kumar D, Wingate D, Ruckebusch Y (1986) Circadian variation in the propagation velocity of the migrating motor complex. Gastroenterology 91:926–930
22. Lemmer B, Nold G (1991) Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 32:627–629
23. Moore JG, Englert E Jr (1970) Circadian rhythm of gastric acid secretion in man. Nature 226:1261–1262
24. Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, Azuma J (2000) Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol 55:861–865
25. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007) Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35:1942–1948. doi:10.1124/dmd.107.016279
26. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132:1107–1118. doi:10.1007/s10549-011-1893-4
27. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017–4025. doi:10.1200/JCO.2012.43.5362
28. Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2014) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. doi:10.1038/tpj.2014.34
29. Singh BN, Malhotra BK (2004) Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43:1127–1156. doi:10.2165/00003088-200443150-00005